The Efficacy and Safety of Ozagrel Sodium Combined with Edaravone in Patients with Acute Cerebral Infarction

Objective To investigate the efficacy and safety of Ozagrel sodium combined with Edaravone in patients with acute cerebral infarction(ACI). Methods Eighty-two ACI patients within 48 hours of onset were enrolled. They were randomly divided into treatment group (42cases) and control group (40 cases). The treatment group was allocated Ozagrel sodium 80mg, Bid, for 14 days and Edaravone 30mg, Bid, for 14 days. And control group was only allocated Ozagrel sodium 80mg, Bid, for 14 days. Therapeutic effect was evaluated by the National Institutes of Health Stroke Scale (NIHSS) and the Bathal index (BI). The liver and renal function, blood and urinary routine, and electrocardiogram (ECG) were detected. Results Compared with the control group, there were significant difference after one week (P0.05) and after two weeks (P0.01) in the grades of NIHSS of treatment group, and significant difference after one or two weeks (P0.05) and after three weeks (P0.01) in the grades of BI of treatment group. There was no side effect in both groups. Conclusion Ozagrel sodium combined with Edaravone is a effective and safe therapy for the ACI patients.